There is this article https://www.reuters.com/business/healthcare-pharmaceuticals/delta-variant-poses-twice-risk-hospitalisation-study-2021-08-27/?utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=facebook&fbclid=IwAR3eP56sM18A-ax1D4oMmlTVZvypotXwTAY8y4inNQGXIlPatkwT-kw2mzs